Biotech News

PureTech Announces Successful End-of-Phase 1 Meeting with U.S . Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)

PureTech Health (PRTC)PureTech Health2026-09-21 06:00 ESTFDA / regulatory

RNS Number: 4709V PureTech Health PLC 21 September 2026 21 September 2026 PureTech Health plc PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic

PureTech Health

Founded-Entity Model PureTech Health creates and advances biotechnology companies around internally identified scientific concepts. Rather than operating as a conventional single-pipeline developer, it retains ownership interests and economic rights across a portfolio of independently financed founded entities. Celea Therapeutics Celea...

Recent company news

PRTCPureTech Health2026-10-07 17:00 EST

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

PRTCPureTech Health2026-09-22 06:00 EST

PureTech Health plc – Half-Year Report

PRTCPureTech Health2026-09-21 06:00 EST